NAD+ news and clinical trials

Dsm-firmenich Switzerland AG registered a Phase 1 study to evaluate the effects of trigonelline monohydrate on NAD+ metabolism, safety, and pharmacokinetics in 60 healthy adults aged 40 to 70. Participants will receive one of four doses of the supplement, an NMN comparator, or a placebo for 4 weeks.

A systematic review published in Frontiers in Neurology details the role of NAD+ depletion in Parkinson's disease pathogenesis. It summarizes evidence that NAD+ precursors like nicotinamide riboside and NMN may offer neuroprotective effects in disease models.

Apothecary Pharma LLC initiated a nationwide Class II recall of Apothecary NAD+ Injection 200 mg/mL, 6 mL sterile multi-dose vials. The recall was issued due to a lack of assurance of sterility.

Beijing Children's Hospital registered a Phase 2 trial of 180 children to determine if injectable nicotinamide adenine dinucleotide is safe and effective for treating cardiac dysfunction. The multicenter study will assess the supplement alongside standard heart failure care.

Reus Research registered a study involving 80 healthy adults to assess the absorption, safety, and efficacy of an oral NAD+ supplement. The trial will compare NAD+ levels in whole blood against a placebo over 56 days.

Massachusetts General Hospital is recruiting 50 healthy adults for a trial to determine if 2 weeks of oral nicotinamide riboside supplementation can increase the NAD+/NADH ratio in the brain. Researchers will use phosphorus 31 MR spectroscopy to measure brain energy metabolism.

Vanderbilt University Medical Center registered a trial to study the effects of Nicotinamide Riboside on NAD+ biology in 10 participants with combined pulmonary hypertension. The study aims to evaluate this vitamin B3 form as a potential option for improving heart and blood vessel function.

Researchers in a randomized controlled trial published in JCI insight found that oral nicotinamide riboside supplementation (500 mg twice daily for 4 weeks) attenuates Th17-driven inflammation in psoriasis patients by inducing the SLIT2-ROBO1 signaling pathway.

Shaklee Corporation completed a pilot trial of 29 healthy adults to evaluate the effects of a proprietary nutritional supplement on NAD+ levels. The study compared the supplement against a placebo control.

AgelessRx registered a pilot randomized controlled trial with 30 participants to investigate if combinations of gerotherapeutics like rapamycin, metformin, and NAD+ impact longevity outcomes. The study explores three different treatment arms, including a control and comprehensive therapy.

The Children's Hospital of Philadelphia posted results for a study of 75 participants with Friedreich's Ataxia that evaluated the effects of Nicotinamide Riboside and exercise on aerobic capacity. The trial used a 2x2 factorial design to measure Peak VO2 and glucose homeostasis.

Shaklee Corporation completed a 29-participant pilot trial evaluating the effects of a proprietary nutritional supplement on NAD+ responses in healthy adults compared to a placebo.

The University of Rhode Island completed a pilot study involving 53 healthy adult females to determine if 4 weeks of oral NAD+ supplementation influences cognitive functioning, inflammatory markers, and indicators of neurodegeneration.

The University of Pennsylvania is recruiting 48 healthy adults for a study measuring NAD levels using magnetic resonance spectroscopy. The trial aims to validate measurements taken before and after oral nicotinamide riboside supplementation.

A systematic review of 113 studies found that while oral nicotinamide riboside and nicotinamide mononucleotide consistently increase NAD levels in humans, clinical effectiveness for anti-aging and wellness outcomes remains inconclusive due to heterogeneous results.

In a randomized controlled trial of 65 healthy participants, researchers determined that oral nicotinamide riboside and nicotinamide mononucleotide increase circulatory NAD+ concentrations by converting into nicotinic acid via gut microbiota, whereas nicotinamide acts differently.

BioNADrx Holdings, Inc. completed an early phase 1 study with 60 healthy adults to investigate the multi-omic impact of a 5 day course of oral LathMized NAD+ supplement. The study assessed changes in biological markers and NAD+ levels within blood cells.

Brigham and Women's Hospital registered a Phase 1 trial to test the safety and tolerability of MIB-626, a microcrystalline form of NMN, in 24 adults with Down syndrome. The study will monitor participants for 28 days of dosing and 28 days of follow-up.

Kaiser Permanente completed a phase 2 trial evaluating oral niacinamide versus placebo for preventing acute kidney injury in 331 patients undergoing on-pump cardiac surgery.

The Children's Hospital of Philadelphia completed a study of 75 participants testing whether Nicotinamide Riboside and exercise training improve aerobic capacity and glucose homeostasis in individuals with Friedreich's Ataxia.

A post hoc analysis of a clinical trial involving 80 healthy middle-aged participants found that baseline NAD levels correlate with inflammatory, lipid, and liver markers. Nicotinamide mononucleotide supplementation-induced increases in NAD were associated with improved red blood cell parameters.